Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maha Ayyoub

Showing results (11-20 of 88) with videos related to

Pageof 9
Sort By:
Cancers|July 8, 2020
Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian CancerAlejandra Martinez, Jean-Pierre Delord, Maha Ayyoub, et al.
Nature Reviews. Clinical Oncology|April 1, 2016
Immunological off-target effects of imatinibLaurence Zitvogel, Sylvie Rusakiewicz, Bertrand Routy, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 11, 2014
Expression of MAGE-A3/6 in primary breast cancer is associated with hormone receptor negative status, high histologic grade, and poor survivalMaha Ayyoub, Clara-Maria Scarlata, Ahmed Hamaï, et al.
Cancer Immunology Research|April 30, 2014
CD4+ T effectors specific for the tumor antigen NY-ESO-1 are highly enriched at ovarian cancer sites and coexist with, but are distinct from, tumor-associated TregMaha Ayyoub, Pascale Pignon, Jean-Marc Classe, et al.
European Journal of Immunology|December 3, 2014
Differential expression of the immunosuppressive enzyme IL4I1 in human induced Aiolos+, but not natural Helios+, FOXP3+ Treg cellsClara-Maria Scarlata, Clotilde Celse, Pascale Pignon, et al.
Haematologica|August 10, 2012
MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancerCaroline Poli, Caroline Raffin, Danijel Dojcinovic, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 27, 2013
Human memory Helios- FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1β by downregulating their suppressor functionsCaroline Raffin, Pascale Pignon, Clotilde Celse, et al.
The Journal of Clinical Investigation|July 12, 2005
A peripheral circulating compartment of natural naive CD4 TregsDanila Valmori, Andrea Merlo, Naira E Souleimanian, et al.
Clinical Immunology (Orlando, Fla.)|August 17, 2005
Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individualsDanila Valmori, Naira E Souleimanian, Charles S Hesdorffer, et al.
Frontiers in Oncology|May 10, 2021
Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?Jonathan Khalifa, Julien Mazieres, Carlos Gomez-Roca, et al.
Pageof 9

Showing results (11-20 of 88) with videos related to

Sort By:
Pageof 9
Cancers|July 8, 2020
Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian CancerAlejandra Martinez, Jean-Pierre Delord, Maha Ayyoub, et al.
Nature Reviews. Clinical Oncology|April 1, 2016
Immunological off-target effects of imatinibLaurence Zitvogel, Sylvie Rusakiewicz, Bertrand Routy, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 11, 2014
Expression of MAGE-A3/6 in primary breast cancer is associated with hormone receptor negative status, high histologic grade, and poor survivalMaha Ayyoub, Clara-Maria Scarlata, Ahmed Hamaï, et al.
Cancer Immunology Research|April 30, 2014
CD4+ T effectors specific for the tumor antigen NY-ESO-1 are highly enriched at ovarian cancer sites and coexist with, but are distinct from, tumor-associated TregMaha Ayyoub, Pascale Pignon, Jean-Marc Classe, et al.
European Journal of Immunology|December 3, 2014
Differential expression of the immunosuppressive enzyme IL4I1 in human induced Aiolos+, but not natural Helios+, FOXP3+ Treg cellsClara-Maria Scarlata, Clotilde Celse, Pascale Pignon, et al.
Haematologica|August 10, 2012
MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancerCaroline Poli, Caroline Raffin, Danijel Dojcinovic, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 27, 2013
Human memory Helios- FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1β by downregulating their suppressor functionsCaroline Raffin, Pascale Pignon, Clotilde Celse, et al.
The Journal of Clinical Investigation|July 12, 2005
A peripheral circulating compartment of natural naive CD4 TregsDanila Valmori, Andrea Merlo, Naira E Souleimanian, et al.
Clinical Immunology (Orlando, Fla.)|August 17, 2005
Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individualsDanila Valmori, Naira E Souleimanian, Charles S Hesdorffer, et al.
Frontiers in Oncology|May 10, 2021
Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?Jonathan Khalifa, Julien Mazieres, Carlos Gomez-Roca, et al.
Pageof 9